AI Article Synopsis
- Lipid injectable emulsions (ILEs) are used in parenteral nutrition to provide energy and essential fatty acids, and their use presents unique challenges compared to oral fats.
- Since 1975, soybean oil has been the primary source for ILEs in the US, but safety concerns and inventory shortages have led to the introduction of new ILE products.
- The paper addresses gaps in best practices for ILEs, aiming to minimize safety errors related to prescribing, compounding, and administration, with Part 1 focusing on adults and Part 2 planned for neonatal and pediatric populations.
Article Abstract
Lipid injectable emulsions (ILEs) are complex pharmaceutical formulations used as a source of energy and essential fatty acids in parenteral nutrition. Issues associated with ILE use are distinctly different from oral fat and arise from emulsion stability, dose, and infusion tolerance. Since 1975, soybean oil has been the consistent source oil used in ILE formulations in the US. Partly because of safety concerns with the soybean-based ILE and frequent and long-standing problems with product inventory shortages, new ILE products have become available. Gaps in ILE best practices create a risk for ILE safety errors in prescribing, compounding, and administration of these products. This paper provides information on appropriate indications, dosing, and methods to avoid potential errors with ILE products in the US. This paper (Part 1) will focus on ILE background, information, and recommendations for adult patients, whereas Part 2 of this series will focus on neonatal and pediatric patient-specific information.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ncp.10496 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!